Trial Profile
Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 29 Apr 2010 Additional trial investigator [Rose A] identified as reported by United Kingdom Clinical Research Network record.
- 29 Apr 2010 New source identified and integrated (United Kingdom Clinical Research Network).
- 18 May 2008 Status changed from initiated to discontinued as reported by ClinicalTrials.gov. This was a result of Pfizer discontinuing the marketing of Exubera.